103 related articles for article (PubMed ID: 15979348)
1. A novel simultaneous modeling approach to estimate linearity of pharmacokinetic parameters, including saturation of intestinal efflux, in the rat.
Williams JA; Sahasrabudhe V; Walton J; Zhu T; Hudson G; Koup JR
J Pharmacol Toxicol Methods; 2005; 52(3):307-13. PubMed ID: 15979348
[TBL] [Abstract][Full Text] [Related]
2. In vivo determination of drug kinetic linearity and individual organ elimination by the accelerated infusion technique.
Li J; Dobson GL; Marietta MP; Rhodes GR; Hidalgo IJ
J Pharmacol Toxicol Methods; 1997 Feb; 37(1):47-53. PubMed ID: 9086288
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol.
Yoon IS; Choi MK; Kim JS; Shim CK; Chung SJ; Kim DD
Xenobiotica; 2011 Mar; 41(3):243-51. PubMed ID: 21128757
[TBL] [Abstract][Full Text] [Related]
4. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability.
Yang SH; Lee MG
Int J Pharm; 2007 Mar; 332(1-2):17-23. PubMed ID: 17157458
[TBL] [Abstract][Full Text] [Related]
5. Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery.
Dohil R; Cabrera BL; Gangoiti JA; Barshop BA; Rioux P
Fundam Clin Pharmacol; 2014 Apr; 28(2):136-43. PubMed ID: 23113697
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
8. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
Yang SH; Lee MG
Biopharm Drug Dispos; 2008 Oct; 29(7):414-26. PubMed ID: 18697186
[TBL] [Abstract][Full Text] [Related]
9. Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat.
Koster AS; Hofman GA; Frankhuijzen-Sierevogel AC; Noordhoek J
Drug Metab Dispos; 1985; 13(4):464-70. PubMed ID: 2863112
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim SH; Lee MG
Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.
Lledó-García R; Nácher A; Casabó VG; Merino-Sanjuán M
Drug Metab Dispos; 2011 Feb; 39(2):294-301. PubMed ID: 20978105
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of maslinic acid, a triterpene from olives, after intravenous and oral administration in rats.
Sánchez-González M; Colom H; Lozano-Mena G; Juan ME; Planas JM
Mol Nutr Food Res; 2014 Oct; 58(10):1970-9. PubMed ID: 25045029
[TBL] [Abstract][Full Text] [Related]
14. Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats.
Matsuda Y; Konno Y; Satsukawa M; Kobayashi T; Takimoto Y; Morisaki K; Yamashita S
Drug Metab Dispos; 2012 Dec; 40(12):2231-8. PubMed ID: 22930277
[TBL] [Abstract][Full Text] [Related]
15. Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
Letendre L; Scott M; Dobson G; Hidalgo I; Aungst B
Pharm Res; 2004 Aug; 21(8):1457-62. PubMed ID: 15359582
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
17. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
18. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.
Liu YT; Hao HP; Xie HG; Lai L; Wang Q; Liu CX; Wang GJ
Drug Metab Dispos; 2010 Oct; 38(10):1779-84. PubMed ID: 20634337
[TBL] [Abstract][Full Text] [Related]
19. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
20. Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration.
Haug KG; Weber B; Hochhaus G; Butterweck V
Eur J Pharm Sci; 2012 Jan; 45(1-2):79-89. PubMed ID: 22085634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
